MX2021003867A - Anticuerpo monoclonal beta amiloide anti-n-truncado humanizado. - Google Patents
Anticuerpo monoclonal beta amiloide anti-n-truncado humanizado.Info
- Publication number
- MX2021003867A MX2021003867A MX2021003867A MX2021003867A MX2021003867A MX 2021003867 A MX2021003867 A MX 2021003867A MX 2021003867 A MX2021003867 A MX 2021003867A MX 2021003867 A MX2021003867 A MX 2021003867A MX 2021003867 A MX2021003867 A MX 2021003867A
- Authority
- MX
- Mexico
- Prior art keywords
- truncated
- monoclonal antibody
- humanized anti
- beta monoclonal
- amiloid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201816210 | 2018-10-04 | ||
| PCT/EP2019/076772 WO2020070225A1 (en) | 2018-10-04 | 2019-10-02 | Humanised anti-n-truncated amyloid beta monoclonal antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003867A true MX2021003867A (es) | 2021-09-08 |
Family
ID=68136417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003867A MX2021003867A (es) | 2018-10-04 | 2019-10-02 | Anticuerpo monoclonal beta amiloide anti-n-truncado humanizado. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12297261B2 (enExample) |
| EP (1) | EP3861023A1 (enExample) |
| JP (1) | JP7610515B2 (enExample) |
| KR (1) | KR102862077B1 (enExample) |
| CN (1) | CN113056480B (enExample) |
| AU (1) | AU2019354714B9 (enExample) |
| BR (1) | BR112021006153A2 (enExample) |
| EA (1) | EA202190954A1 (enExample) |
| IL (1) | IL281979B2 (enExample) |
| MX (1) | MX2021003867A (enExample) |
| SG (1) | SG11202102765RA (enExample) |
| WO (1) | WO2020070225A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| CN115698060A (zh) | 2020-03-10 | 2023-02-03 | 生命爱科 | 环肽 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| WO2024133925A1 (en) | 2022-12-22 | 2024-06-27 | Bioarctic Ab | Antibody which binds to abetape3 |
| WO2025262228A1 (en) | 2024-06-20 | 2025-12-26 | Bioarctic Ab | Bispecific binding molecule |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US474900A (en) | 1892-05-17 | William byrnes | ||
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| HUE033325T2 (en) * | 2007-01-05 | 2017-11-28 | Univ Zuerich | Anti-beta-amyloid binder antibodies and their use |
| CN101883792B (zh) | 2007-10-29 | 2014-08-27 | 基因创新有限公司 | 特异于β-淀粉状蛋白肽的新抗体以及其用作诊断剂或药物的用途 |
| US8795664B2 (en) | 2010-06-04 | 2014-08-05 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Monoclonal antibodies targeting amyloid beta oligomers |
| DK3269736T3 (da) * | 2012-05-10 | 2020-01-13 | Georg August Univ Goettingen Stiftung Oeffentlichen Rechts Univsmedizin | Konformationsspecifikke antistoffer mod oligomerer af amyloid beta |
| WO2015173133A1 (en) | 2014-05-12 | 2015-11-19 | Chiesi Farmaceutici S.P.A. | Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy |
| NZ739181A (en) * | 2015-07-16 | 2023-05-26 | Vivoryon Therapeutics N V | Anti-pyroglutamated amyloid beta humanized antibodies |
| CN111518206B (zh) * | 2019-02-01 | 2022-03-29 | 长春金赛药业有限责任公司 | 人源化抗Aβ单克隆抗体及其应用 |
| CN115698060A (zh) * | 2020-03-10 | 2023-02-03 | 生命爱科 | 环肽 |
-
2019
- 2019-10-02 KR KR1020217012796A patent/KR102862077B1/ko active Active
- 2019-10-02 SG SG11202102765RA patent/SG11202102765RA/en unknown
- 2019-10-02 JP JP2021543565A patent/JP7610515B2/ja active Active
- 2019-10-02 MX MX2021003867A patent/MX2021003867A/es unknown
- 2019-10-02 AU AU2019354714A patent/AU2019354714B9/en active Active
- 2019-10-02 EA EA202190954A patent/EA202190954A1/ru unknown
- 2019-10-02 WO PCT/EP2019/076772 patent/WO2020070225A1/en not_active Ceased
- 2019-10-02 IL IL281979A patent/IL281979B2/en unknown
- 2019-10-02 US US17/282,592 patent/US12297261B2/en active Active
- 2019-10-02 CN CN201980065883.5A patent/CN113056480B/zh active Active
- 2019-10-02 BR BR112021006153-3A patent/BR112021006153A2/pt unknown
- 2019-10-02 EP EP19782593.8A patent/EP3861023A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113056480B (zh) | 2025-06-13 |
| CA3114669A1 (en) | 2020-04-09 |
| KR102862077B1 (ko) | 2025-09-18 |
| WO2020070225A1 (en) | 2020-04-09 |
| EA202190954A1 (ru) | 2021-06-29 |
| AU2019354714B2 (en) | 2026-05-21 |
| JP2022513331A (ja) | 2022-02-07 |
| AU2019354714A1 (en) | 2021-04-29 |
| CN113056480A (zh) | 2021-06-29 |
| IL281979B1 (en) | 2025-05-01 |
| IL281979B2 (en) | 2025-09-01 |
| US20230203140A9 (en) | 2023-06-29 |
| US12297261B2 (en) | 2025-05-13 |
| KR20210080400A (ko) | 2021-06-30 |
| AU2019354714B9 (en) | 2026-07-02 |
| EP3861023A1 (en) | 2021-08-11 |
| SG11202102765RA (en) | 2021-04-29 |
| JP7610515B2 (ja) | 2025-01-08 |
| IL281979A (en) | 2021-05-31 |
| US20210347867A1 (en) | 2021-11-11 |
| BR112021006153A2 (pt) | 2021-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202190954A1 (ru) | Гуманизированное моноклональное антитело против n-укороченного бета-амилоида | |
| EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
| EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
| PH12020552018A1 (en) | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies | |
| EA201270813A1 (ru) | АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| EA201891909A1 (ru) | TGFβ1-СВЯЗЫВАЮЩИЕ ИММУНОГЛОБУЛИНЫ И ИХ ПРИМЕНЕНИЕ | |
| EA202092847A1 (ru) | Антитела к cd3 и их применение | |
| EA201992163A1 (ru) | АНТИТЕЛА К БЕТА-АМИЛОИДНОМУ ПЕПТИДУ N3pGlu И ИХ ПРИМЕНЕНИЕ | |
| CO2021001742A2 (es) | Anticuerpos anti–sortilina y métodos para su uso | |
| EA201790342A1 (ru) | Антитела к trem2 и способы их применения | |
| EA202190235A1 (ru) | Антитела к cd33 и способы их применения | |
| EA201792657A1 (ru) | Связывающие lag-3 молекулы и способы их применения | |
| MA42542B1 (fr) | Molécules se liant à pd-1 et méthodes d'utilisation correspondantes | |
| EP4374922A3 (en) | Anti-c5 antibodies and uses thereof | |
| JOP20180117B1 (ar) | أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها | |
| EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
| MX2022012182A (es) | Metodos de uso de anticuerpos anti-trem2. | |
| EA202092420A1 (ru) | Антитело против pd-l1 и его применение | |
| PH12021552148A1 (en) | Cd3 binding molecules | |
| NZ743713A (en) | Human immunodeficiency virus neutralizing antibodies | |
| IL289488A (en) | Monoclonal antibodies that bind egfrviii and their use | |
| EA201892427A1 (ru) | ГУМАНИЗИРОВАННЫЕ АНТИ-FcRn АНТИТЕЛА С СОЗРЕВШЕЙ АФФИННОСТЬЮ | |
| EA201990895A1 (ru) | Антитела к о1 и варианты их применения | |
| EA202192907A1 (ru) | Моноклональное антитело, которое специфически связывается с gitr |